BMS 986325
Alternative Names: BMS-986325; Y 12XX-hz28-P238KLatest Information Update: 28 Mar 2024
At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Sjogren's syndrome
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Sjogren's-syndrome in Germany (IV)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Sjogren's-syndrome in Germany (SC)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Sjogren's-syndrome in USA (IV)